Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancer COSTAR, a Phase 2 trial of JEMPERLI plus cobolimab, an anti-TIM-3 antagonist antibody licensed to TESARO , Inc.

SAN DIEGO , Sept. 12, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that the company has sold its royalty interest on future global net sales of Zejula to a wholly-owned

Imsidolimab (anti-IL-36 receptor antagonist) did not demonstrate improvement over placebo in the primary endpoint and key secondary endpoints Imsidolimab was safe and well tolerated with no imsidolimab-related serious or severe adverse events reported Company to discontinue imsidolimab clinical